Tag Archives: Ryan Zimmerman

NuVasive (NUVA) Gets a Buy Rating from BTIG

BTIG analyst Ryan Zimmerman maintained a Buy rating on NuVasive (NUVA – Research Report) on June 27 and set a price target of $65. The company’s shares closed on Friday at $58.54. According to TipRanks.com, Zimmerman is a top 100

Analysts Are Neutral on These Healthcare Stocks: Glaukos (GKOS), Varian Medical Systems (VAR)

Analysts fell to the sidelines weighing in on Glaukos (GKOS – Research Report) and Varian Medical Systems (VAR – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Glaukos (GKOS) BTIG analyst

Organogenesis Holdings Inc (ORGO) Gets a Buy Rating from BTIG

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings Inc (ORGO – Research Report) on May 10 and set a price target of $12. The company’s shares closed on Friday at $7.01, close to its 52-week low of

BTIG Keeps a Hold Rating on Glaukos (GKOS)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on Glaukos (GKOS – Research Report). The company’s shares closed yesterday at $69.91. Zimmerman wrote: “We maintain our Neutral rating on GKOS shares following a solid 1Q19

BTIG Sticks to Its Buy Rating for AxoGen (AXGN)

BTIG analyst Ryan Zimmerman reiterated a Buy rating on AxoGen (AXGN – Research Report) on May 8 and set a price target of $29. The company’s shares closed yesterday at $23.92. Zimmerman wrote: “Raise PT to $29 We reiterate our

BTIG Sticks to Its Buy Rating for OrthoPediatrics Corp (KIDS)

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on OrthoPediatrics Corp (KIDS – Research Report), with a price target of $44. The company’s shares closed yesterday at $40.81. Zimmerman observed: “We maintain our Buy rating